(TYRA) Tyra Biosciences - Overview
Stock: FGFR, Precision, Platform, Oncology, Skeletal
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 62.5% |
| Relative Tail Risk | -8.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.51 |
| Alpha | 106.30 |
| Character TTM | |
|---|---|
| Beta | 0.977 |
| Beta Downside | 0.787 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.32% |
| CAGR/Max DD | 0.44 |
Description: TYRA Tyra Biosciences December 26, 2025
Tyra Biosciences (NASDAQ:TYRA) is a clinical-stage biotech focused on precision medicines that modulate fibroblast growth factor receptor (FGFR) pathways. Its proprietary SNÅP platform iteratively maps molecular structures to anticipate genetic alterations, aiming to accelerate drug design for oncology and rare FGFR-driven disorders. The lead candidate, TYRA-300, is in Phase 1/2 trials for metastatic urothelial carcinoma and other solid tumors, with parallel programs targeting FGFR3-related skeletal dysplasias; additional pipelines include TYRA-200 for biliary and solid tumors and TYRA-430 for hepatocellular carcinoma.
Key quantitative signals (as of the most recent 10-Q filing, Q2 2024) show a cash position of roughly $115 million, giving the company an estimated 12-month runway at current burn rates of $9-10 million per quarter. The global FGFR-targeted oncology market is projected to grow at a CAGR of ~12% through 2030, driven by rising prevalence of FGFR-altered cancers and expanding companion-diagnostic adoption. However, the company’s valuation is highly sensitive to trial outcomes; a 30% probability-adjusted success rate for Phase 2 oncology assets (industry baseline) would imply a modest risk-adjusted market-cap upside of ~15% if TYRA-300 meets its primary endpoints.
For a deeper quantitative assessment, you might explore ValueRay’s analyst tools to model scenario-based valuations.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -111.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA -13.14 > 1.0 |
| NWC/Revenue: 53.5k% < 20% (prev 70.4k%; Δ -16.9k% < -1%) |
| CFO/TA -0.30 > 3% & CFO -91.1m > Net Income -111.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.7m) vs 12m ago 1.35% < -2% |
| Gross Margin: 42.94% > 18% (prev 0.05%; Δ 4289 % > 0.5%) |
| Asset Turnover: 0.15% > 50% (prev 0.13%; Δ 0.01% > 0%) |
| Interest Coverage Ratio: -10.95 > 6 (EBITDA TTM -122.4m / Interest Expense TTM -11.2m) |
Altman Z'' -15.00
| A: 0.88 (Total Current Assets 281.2m - Total Current Liabilities 15.9m) / Total Assets 301.9m |
| B: -1.12 (Retained Earnings -337.4m / Total Assets 301.9m) |
| C: -0.36 (EBIT TTM -122.9m / Avg Total Assets 341.2m) |
| D: -15.79 (Book Value of Equity -337.0m / Total Liabilities 21.3m) |
| Altman-Z'' Score: -16.88 = D |
Beneish M -2.91
| DSRI: 1.17 (Receivables 2.20m/1.90m, Revenue 496.0k/502.0k) |
| GMI: 0.12 (GM 42.94% / 4.98%) |
| AQI: 2.45 (AQ_t 0.05 / AQ_t-1 0.02) |
| SGI: 0.99 (Revenue 496.0k / 502.0k) |
| TATA: -0.07 (NI -111.7m - CFO -91.1m) / TA 301.9m) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of TYRA shares?
Over the past week, the price has changed by -1.00%, over one month by +17.04%, over three months by +105.13% and over the past year by +125.42%.
Is TYRA a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TYRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.9 | 23.1% |
| Analysts Target Price | 37.9 | 23.1% |
| ValueRay Target Price | 35.1 | 14.1% |
TYRA Fundamental Data Overview January 31, 2026
Revenue TTM = 496.0k USD
EBIT TTM = -122.9m USD
EBITDA TTM = -122.4m USD
Long Term Debt = 5.92m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 456.0k USD (from shortTermDebt, last quarter)
Debt = 5.92m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -56.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.46b USD (1.73b + Debt 5.92m - CCE 274.9m)
Interest Coverage Ratio = -10.95 (Ebit TTM -122.9m / Interest Expense TTM -11.2m)
EV/FCF = -15.98x (Enterprise Value 1.46b / FCF TTM -91.2m)
FCF Yield = -6.26% (FCF TTM -91.2m / Enterprise Value 1.46b)
FCF Margin = -18.4k% (FCF TTM -91.2m / Revenue TTM 496.0k)
Net Margin = -22.5k% (Net Income TTM -111.7m / Revenue TTM 496.0k)
Gross Margin = 42.94% ((Revenue TTM 496.0k - Cost of Revenue TTM 283.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.83 (Enterprise Value 1.46b / Total Assets 301.9m)
Interest Expense / Debt = 41.46% (Interest Expense 2.45m / Debt 5.92m)
Taxrate = 21.0% (US default 21%)
NOPAT = -97.1m (EBIT -122.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.71 (Total Current Assets 281.2m / Total Current Liabilities 15.9m)
Debt / Equity = 0.02 (Debt 5.92m / totalStockholderEquity, last quarter 280.5m)
Debt / EBITDA = 0.46 (negative EBITDA) (Net Debt -56.0m / EBITDA -122.4m)
Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -56.0m / FCF TTM -91.2m)
Total Stockholder Equity = 312.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.73% (Net Income -111.7m / Total Assets 301.9m)
RoE = -35.76% (Net Income TTM -111.7m / Total Stockholder Equity 312.3m)
RoCE = -38.62% (EBIT -122.9m / Capital Employed (Equity 312.3m + L.T.Debt 5.92m))
RoIC = -31.09% (negative operating profit) (NOPAT -97.1m / Invested Capital 312.3m)
WACC = 9.60% (E(1.73b)/V(1.73b) * Re(9.52%) + D(5.92m)/V(1.73b) * Rd(41.46%) * (1-Tc(0.21)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.85%
Fair Price DCF = unknown (Cash Flow -91.2m)
EPS Correlation: -1.67 | EPS CAGR: 30.93% | SUE: 4.0 | # QB: 1
Revenue Correlation: 20.41 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.57 | Chg30d=-0.006 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.21 | Chg30d=+0.052 | Revisions Net=+1 | Growth EPS=-12.0% | Growth Revenue=+0.0%